Marc is an IP partner in The Hague. He has substantial experience in intellectual property litigation, particularly in the field of patents (pharmaceuticals, chemical, electronic and mechanical engineering), pharmaceutical advertising, trademarks and copyright.
Marc has in-depth knowledge of cross-border European patent litigation, particularly in the life sciences area. Marc gained his reputation as a patent litigator in this complex field in the big international dispute between Teva Pharmaceuticals and MSD regarding alendronate (MSD's blockbuster drug Fosamax), wherein he successfully acted for Teva in multiple cases before the Dutch court, and also before the Opposition Division of the EPO. Marc has since handled many high-stakes patent disputes for Teva, and is still doing so, and also acts for its recently acquired company Ratiopharm. Marc is Teva's go-to counsel in the Netherlands, and also advises them on their pan-European patent protection strategy.
This year Marc was praised by the legal research publication IAM Patent Litigation 250 as one of the world's leading patent litigators, noting that 'Marc wins praise for his 'thoroughness, attention to detail and comprehensive understanding of all the issues in a case'.'
Marc has also represented clients before the European Court of Justice.
According to Chambers Europe 2013 Marc has 'noted expertise in life sciences' and 'specialises in pharmaceuticals and biotechnology, and is highly recommended for patent work in these sectors. Chambers Europe 2011 says 'He has 'a practical approach and a strong personality'.'
This biography is an extract from The International Who's Who of Life Sciences Lawyers which can be purchased from our Shop.
Marc van Wijngaarden also features in the following practice areas:
It is not possible to buy entry into any Who's Who Legal publication
Nominees have been selected based upon comprehensive, independent survey work with both general counsel and private practice lawyers worldwide. Only specialists who have met independent international research criteria are listed.